Erasca, Inc. (ERAS)
| Market Cap | 3.08B +919.9% |
| Revenue (ttm) | n/a |
| Net Income | -124.55M |
| EPS | -0.44 |
| Shares Out | 310.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,264,324 |
| Open | 10.51 |
| Previous Close | 19.15 |
| Day's Range | 8.70 - 10.60 |
| 52-Week Range | 1.06 - 24.28 |
| Beta | 1.05 |
| Analysts | Strong Buy |
| Price Target | 14.25 (+43.94%) |
| Earnings Date | May 8, 2026 |
About ERAS
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ERAS stock is "Strong Buy." The 12-month stock price target is $14.25, which is an increase of 43.94% from the latest price.
News
Erasca Stock Sinks 50% in Race for ‘Miracle' Cancer Drug. What's Behind the Historic Sell-Off.
Erasca is developing a competitor to Revolution Medicines' daraxonrasib.
Erasca, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Erasca, Inc. (NASDAQ: ERAS). The investigation focuses on Erasca's execut...
Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday?
Erasca Inc. (NASDAQ:ERAS) said it intends to vigorously contest allegations made by Revolution Medicines, Inc. (NASDAQ:RVMD).
Erasca shares sink after patient death in early-stage cancer drug trial
Erasca shares fell over 35% before the bell on Tuesday after the company disclosed a patient death in an early-stage trial of its experimental cancer drug, even though analysts said the incident was...
Erasca Transcript: Study result
Preliminary Phase I data for ERAS-0015 show strong efficacy and safety in RAS-mutated lung and pancreatic cancers, with response rates surpassing comparators and early evidence of combinability with anti-EGFR therapy. Most patients remain on treatment, and further expansion and combo data are expected in H1 2027.
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015's promising early clinical data underscore its potential to be a best-in-class RAS-targeti...
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, Mar...
Erasca Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company is advancing two lead RAS-targeted programs, ERAS-0015 and ERAS-4001, with promising early clinical data showing high potency and favorable safety. Rapidly enrolling trials will provide key updates in 2024, and future combination strategies are planned.
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase 1 ...
Erasca Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The discussion highlighted strong preclinical and early clinical data for both pan-RAS and pan-KRAS inhibitors, emphasizing differentiated potency, PK, and safety profiles. Upcoming data will inform dose expansion and combination strategies, with a focus on major solid tumors.
Erasca to Present at Upcoming Conferences in February
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...
Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday?
Erasca Inc. (NASDAQ: ERAS) stock is trading lower on Monday, though there is no news to justify the movement.
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...
Erasca Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...
Erasca Announces Proposed Public Offering of $150 Million of Common Stock
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...
Erasca Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted strong preclinical and early clinical data for two lead RAS-targeting programs, with ERAS-15 showing high potency and favorable safety at low doses. Both programs are advancing through clinical trials, with key data readouts expected this year.
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones
Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for E...
What's Going With Cancer Biotech Erasca Stock On Thursday?
Erasca Inc. (NASDAQ: ERAS) shares on Wednesday jumped close to 60% to $6.12. On Thursday, the stock fell as low as $4.33.
Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...
Erasca Transcript: Evercore ISI 8th Annual HealthCONx Conference
Two innovative RAS-targeted assets are advancing, with ERAS-0015 showing superior preclinical potency and PK versus competitors, and ERAS-4001 offering a unique scaffold and broad mutation coverage. Early clinical data for both are expected in 2026, with aggressive development enabled by strong financial resources.
Erasca to Present at the 8th Annual Evercore Healthcare Conference
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...
Erasca Transcript: Jefferies London Healthcare Conference 2025
The company is advancing two lead precision oncology programs, ERAS-0015 and ERAS-4001, both in phase one trials targeting RAS-driven cancers. Initial data readouts are expected in 2026, with strong preclinical differentiation and a robust financial position supporting an aggressive development plan.